Two years after the approval of Fiasp faster-acting insulin in adults, Novo Nordisk has announced the FDA approval of Fiasp for use as a new mealtime insulin option for children with diabetes. A sort of acronym for faster-acting insulin asparte, Fiasp starts working within two minutes of injection and can even be effective in lowering blood sugar when taken up to 20 minutes after a meal. It is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
“Managing diabetes can be challenging for parents and caregivers given it is hard to know exactly how much or how quickly their children will eat, making mealtime insulin dosing difficult. Conventional rapid-acting insulins must be administered ahead of meals, which requires some guesswork to dose properly, and children living with diabetes may not achieve adequate blood sugar control.”
According to Novo Nordisk, Fiasp, “has its maximum effect between 1 and 3 hours after the injection and the effect lasts for 3 to 5 hours.”
Fiasp is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
In today’s press release, Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk says, “As a parent of a son living with type 1 diabetes, I know first-hand how tough it can be to address the inevitable blood sugar spikes around mealtimes,” said “Children can be unpredictable and having the option of a fast-acting insulin that doesn’t require pre-meal dosing like Fiasp is a welcome development for the diabetes community.”
The approval is based on the FDA’s review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp® in children.
For information on cost and savings offers, including co-pay and patient assistance programs, visit myfiaspcost.com.
